2013 Researcher Dr. Mark Ruschin

Comparison of healthy tissue sparing using different radiation delivery devices for focal irradiation of multiple brain metastases

Dr. Mark Ruschin brain tumour researcherDr. Mark Ruschin
Sunnybrook Odette Cancer Centre, Toronto, ON
Award: $18,500

Dr. Ruschin's project is funded in memory of and through the generosity of Donald J.T.A. de Jong



Project Summary:

Brain metastases occur in 20-40% of people with cancer, and will lead to over 7,000 diagnosed cases in 2013. For these individuals, quality of life is of the utmost importance. The traditional approach to managing patients with brain metastases is to perform whole brain radiation, in which the entire brain receives a uniform dose of radiation in order to stop the diagnosed brain metastases from growing, and to prevent new brain metastases from forming.

Whole brain radiotherapy, however, adversely affects cognitive function and limits further treatment should additional brain metastases develop. Focal radiation targets individual brain metastases and spares the healthy brain, which maintains better cognitive function and provides excellent tumor control. Various radiation therapy technologies are capable of focal radiation.

One new device has recently become Health Canada approved and exhibits improved characteristics over predecessors such as faster radiation delivery, and lower leakage radiation. We hypothesize that this new device can be used to treat patients with multiple brain metastases in a focal/ablative fashion, thus better preserving patients’ cognitive function and improving quality of life. The focus of this work is technique development and a comparison of radiation dose distributions to the current standard.

Final report:

The project involved development and evaluation of an arc-based technique using an emerging technology to effectively delivery focal radiation to multiple brain metastases. In 2013, the Agility linear accelerator (Elekta AB, Stockholm, Sweden) was just coming to market in Canada and consisted of features that could potentially reduce the normal tissue radiation dose received by the brain compared to the existing systems at that time. The primary objective was thus to implement the technique and measure reduction in normal brain tissue radiation dose compared to our standard technique. Additionally, we needed an improved method for quality assurance (QA) of the device to ensure safe treatment. Read more from the final report (PDF)

Read more from this publication, published by the British Institute of Radiology.

<back to 2013 Research Grant Awardees

Share This

Featured Story

Piper's Story: a dream more precious than Olympic gold

Hi, I am Piper Gilles. You may know me as a world-famous ice dancer. I competed in the PyeongChang 2018 Olympic Winter Games. I am a 7 time world team member and a 7 time Canadian medalist. But the title that means the most to me is far more personal. It’s that of daughter to my amazing mother Bonnie Gilles, who I lost to glioblastoma on May 27, 2018.

Learn more

Spotlight

Doug's Adventure

I am Doug, I have brain cancer; I am told it is terminal, but the “good” kind of terminal. I can assure you that receiving that news...

Learn more

Kathy's Volunteer Profile

Kathy shares her story of volunteering for Brain Tumour Foundation of Canada as part of National Volunteer Week. “I am proud and happy...

Learn more

Upcoming Events

  • 18/Jun/2019: North Bay Support Group: Meets at St. Luke's Catholic Elementary School, 225 Milani Road, North Bay.... Learn more >
  • 18/Jun/2019: New Glasgow Support Group: Meets at East Haven Manor, 695 East River Road in New Glasgow, NS ... Learn more >
  • 19/Jun/2019: Windsor Support Group: Meets at the United Way, Unit A1, 300 Giles Blvd. East... Learn more >
  • 19/Jun/2019: Calgary Support Group: Meets at Wellspring Calgary, 1404 Home Road NW, Calgary, Alberta, T3B 1G7... Learn more >
View All Events >
Thank you to the donors whose contributions make this website and all programs, services and research possible.

Copyright © 2019 Brain Tumour Foundation of Canada. Charitable Registration #BN118816339RR0001